A Phase IIb Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 µg/h, 10 µg/h) Given Intravenously to Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)

Inclusion Criteria:

- Male and non-pregnant, non-lactating female subjects, age >/= 18 years of age; or
women without childbearing potential defined as postmenopausal women aged 55 years or
older, women with bilateral tubal ligation, women with bilateral ovariectomy, and
women with a hysterectomy

- Subjects must have the clinical diagnosis of Congestive Heart Failure (CHF) made at
least three months prior to enrollment

- Subjects must experience worsening of both of the symptoms below leading to
hospitalization at the time of entry into the study:

- dyspnea and

- clinical evidence of volume overload

Exclusion Criteria:

- Acute de-novo heart failure

- Acute myocardial infarction and/or myocardial infarction within 30 days

- Valvular heart disease requiring surgical intervention during the course of the study

- Heart failure due to or associated with uncorrected primary valvular disease,
malfunctioning artificial heart valve, or uncorrected congenital heart disease

- Primary hypertrophic cardiomyopathy

- Acute inflammatory heart disease, eg, acute myocarditis

- Unstable angina requiring angiography